The treatment of rheumatoid arthritis with gold results in adverse reactions in about 30% of patients, of which most are cutaneous,' often necessitating the discontinuation of treatment. A pityriasis rosea-like eruption is recognised to occur as a consequence of treatment with sodium aurothiomalate.2 The mechanism of this reaction is uncertain although eosinophilia3 and increased levels of IgE4 have been reported to be associated with and predict the development of toxicity from gold. A pityriasiform rash has also been reported after treatment with captopril' and is thought to result from a toxic dose dependent reaction.
The treatment of rheumatoid arthritis with gold results in adverse reactions in about 30% of patients, of which most are cutaneous,' often necessitating the discontinuation of treatment. A pityriasis rosea-like eruption is recognised to occur as a consequence of treatment with sodium aurothiomalate. 2 The mechanism of this reaction is uncertain although eosinophilia3 and increased levels of IgE4 have been reported to be associated with and predict the development of toxicity from gold. A pityriasiform rash has also been reported after treatment with captopril' and is thought to result from a toxic dose dependent reaction.
We have studied pityriasiform and discoid eczematous reactions occurring in patients with rheumatoid arthritis and report here the conditions associated with the development of a rash and its subsequent course.
Patients and methods All patients seen in a rheumatology drug monitoring clinic over a period of 18 months who developed a suspected cutaneous reaction to drugs used to treat their rheumatoid arthritis were reviewed in a dermatology clinic. Where possible a specific dermatological diagnosis was made and in all patients, where consent was given, a skin biopsy sample was taken for studies of histology and immunofluorescence, together with blood for a full and differential (fig 2) , usually on the limbs. Of these 17, all but one patient, who was receiving chloroquine, were being treated with gold (12 with aurothiomalate and four with auranofin). There was no relation to the type of non-steroidal anti-inflammatory drug being used. The mean (SD) age at onset of the rash was 55 (15 5) years and the patients consisted of 11 women and five men of whom 12 were seropositive with a disease duration of 9-8 (8-4) years. The time from the start of treatment to the onset of the eruption was 5-5 (2-8) months for the pityriasiform rash and 11 -2 (6 3) months for discoid eczema The histology of the lesions in five patients with pityriasis rosea and five patients with discoid eczema confirmed the clinical impression. Pityriasiform reactions showed a mild superficial perivascular lymphocytic infiltrate with focal spongiosis and parakeratosis of the epidermis. Discoid eczemas showed superficial perivascular lymphocytic infiltrates with spongiosis and vesicle formation. There was often diffuse parakeratosis with the formation of scale crust. Immunofluorescence was usually negative but in four patients showed granular deposition of IgM, occasionally with C3, at the basement membrane. Table 2 summarises the  results of blood tests and table 3 gives the comparable results in 15 control subjects. Despite the rash, the patient and doctor wished to continue gold treatment because of the clinical improvement in the arthritis.
In six patients (three with pityriasis rosea, three with discoid eczema) gold treatment (all but one treated with aurothiomalate) was discontinued with resolution of the rash. The resumption of treatment in four patients resulted in a recurrence in three (one pityriasis rosea receiving auranofm, two with discoid eczema), confirming the relation to gold. The lack of recurrence in one patient and the occurrence at a time when the patients were likely to have a maximum load of gold suggested that the rash might be dose related rather than occurring through an allergic mechanism.
In the three patients in whom the rash recurred and in the next 10 patients who developed a similar eruption, gold treatment was continued and the rash was treated with topical betamethasone valerate ointment, with resolution in seven patients, or, in addition, a reduction in the dose or frequency of gold treatment, with resolution in three patients. In three patients gold was discontinued because of persisting symptoms. In no patient did a generalised erythroderma develop. 4 in which the type of Figure 3 Comparison oflymphocyte proliferation with gold skin eruption was not specified, which found an dose in patients and control subjects.
increased eosinophil count and total IgE with cutaneous gold toxicity, though a subsequent study found no relation with total IgE.8
The results of patch tests and prick tests in Additionally, the finding that patch and intratwo patients with pityriasis rosea and one with dermal tests were negative and that lymphocyte discoid eczema were negative at 30 minutes as proliferation to gold in patients was comparable were the intradermal tests at 30 minutes and 48 with that in control sub ects confirms earlier hours. Figure 3 summarises the results of the findings9 that delayed type hypersensitivity lymphocyte proliferation assays. The control does not play a part in cutaneous gold toxicity, subjects were four patients without rheumatoid though the type of reaction in this study was not arthritis who had not received gold. The results specified. The observation that lymphocytes of stimulation with phytohaemagglutinin were from some patients and control subjects reacted on average 53 times the basal values in patients non-specifically with gold was interesting but of and 26 times the basal values in control subjects. uncertain relevance. At several concentrations of gold there was no If the rash had been allergic in nature it difference between the patients and control would be expected that the eruption would subjects. It is generally assumed that an increase continue as long as treatment with gold was over basal values of two to three times denotes a given. In seven patients, however, the rash was positive response in a lymphocyte proliferation controlled with topical treatment without a assay. In our patients there was a proliferative reduction in gold dose and in a further three response at lower concentrations of gold (20-40 patients the rash was controlled by a reduction [ig/ml) which was present in both patients and in dose or the frequency of gold treatment.
control subjects, implying that this was a non-Support for a possible dose related effect comes specific response and not indicative of an from the finding that gold can inhibit prostaimmunological reaction. At higher concen-glandin synthesis and two human epidermal trations (160 [tg/ml) a toxic effect on lympho-enzymes in vitro.10 Topical steroids may cytes was seen with a low uptake of tritiated antagonise a biochemical alteration induced by thymidine associated with cell death. gold explaining why the rash resolved despite an unchanged gold dose. This is at variance with a previous study" which found no relation Discussion between 'gold dermatitis' (type unspecified) and All but one of the patients seen with a pity-cutaneous gold levels in four patients. In three riasiform or discoid eczematous reaction were of our patients who did not respond to a topical receiving treatment with gold. This suggests a steroid the rash resolved with continued relation with gold rather than the coincidental treatment and a reduction in gold dose. In no occurrence of an idiopathic disease in a patient patient did an exfoliative dermatitis develop with rheumatoid arthritis. Pityriasis rosea-like despite continued treatment with gold. eruptions have long been a recognised compliThe improvement in the erythrocyte sedication of treatment with aurothiomalate.2 Our mentation rate and levels of C reactive protein, findings after rechallenging with gold confirm which are associated with disease control, with that they and rashes resembling discoid eczema the development of the pityriasiform and are reactions to gold (auranofin and aurothio-discoid eczematous reactions confirms earlier malate). In all cases where it was performed, findings that gold associated skin rashes occur histology confirmed the clinical diagnosis. It is at a time when the arthritis is going into our impression that the pityriasiform reaction remission.'2 We suggest that this occurs and discoid eczema are two ends of a spectrum. because the patient is adequately loaded with One patient initially developed pityriasis rosea gold and that it is a dose related, not allergic, which subsequently developed into discoid reaction which can generally be managed with eczema. In addition, the histology of discoid topical treatment or a reduction in dose of gold. eczema is a more florid form of that seen in
In conclusion, we have reported 16 patients pityriasis rosea. The finding of granular deposits with a spectrum from pityriasiform to discoid eczematous response to treatment with gold. We suggest that this is related to the accumulation of gold within the body. If a treatment response is being obtained, gold can be continued with treatment of the skin rash initially with a potent topical steroid and, if this is ineffective, a reduction in the dose or frequency of gold administration.
